Dupixent approved in the US as the first-ever biologic medicine for patients with COPD         Dupixent is indicated for the approximately 300,000 adults in the US with inadequately ...

Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on ...

Sanofi announced today that its Q3 2024 Aide mémoire is available on the "Investors" page of the company's website: ...

Third quarter 2021 results were reviewed by management during a conference call with the financial community. The presentation was followed by a Q&A session. The third quarter of 2021 marked an ...

EADV: New data reinforce Sanofi’s innovative approach and leadership across immune-mediated skin diseases 24 abstracts for Dupixent, including 4 oral presentations, highlight impact of ...

Sometimes transformative technology comes from unexpected places. In drug development, that often means the intersection of seemingly unrelated technologies or esoteric areas of science. French ...

Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly ...

We want to build a healthier, more resilient world. We turn the impossible into the possible by discovering, developing, and delivering medicines and vaccines for millions of people around the world.

Please complete this form to contact Sanofi Canada. All information you provide will be maintained in accordance with our privacy policy. We provide product information and cannot offer medical advice ...

Nous sommes fiers d’être partenaire Premium des Jeux olympiques et paralympiques de Paris 2024. La science et le sport ont beaucoup en commun. Comme les athlètes, nous repoussons nos limites pour ...

A Million Conversations is Sanofi’s global initiative to rebuild trust in healthcare with the underrepresented. Specifically with Black and ethnic minority groups, women, people with disabilities, and ...

At Sanofi, we’re proud to be premium partner of Paris 2024. Like Olympians and Paralympians, we spend every day challenging ourselves and each other to be better, go further, and to never, ever settle ...